[Pubmed] Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
Posté : 16 nov. 2022 12:00
Immune Netw. 2022 Sep 21;22(5):e37. doi: 10.4110/in.2022.22.e37. eCollection 2022 Oct.
ABSTRACT
Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific autoimmunity. Therefore, B cell depletion with monoclonal Abs targeting B cell lineage markers is standard care therapy for several B cell-mediated autoimmune disorders. In the last 5 years, genetically-engineered cellular immunotherapies targeting B cells have shown superior efficacy and long-term remission of B cell malignancies compared to historical clinical outcomes using B cell depletion with monoclonal Ab therapies. This has raised interest in understanding whether similar durable remission could be achieved with use of genetically-engineered cell therapies for autoimmunity. This review will focus on current human clinical trials using engineered cell therapies for B cell-associated autoimmune diseases.
PMID:36381961 | PMC:PMC9634148 | DOI:10.4110/in.2022.22.e37
Source: https://pubmed.ncbi.nlm.nih.gov/3638196 ... 9&v=2.17.8